North America Dermal Fillers Market

North America Dermal Fillers Market Size (2023 to 2028)

The North American dermal fillers market is predicted to be growing at a CAGR of 6.09% from 2023 to 2028. The market size is estimated to be worth USD 3.55 billion by 2028 from USD 2.64 billion in 2023.

The growing demand for cosmetic procedures in North America majorly drives the growth of the North American dermal fillers market. The U.S. witnessed approximately 3.6 million cosmetic surgeries in 2021, with 1.8 million of them being dermal filler procedures. Dermal fillers, such as soft tissue, lip, facial, and wrinkle fillers, are widely used as gel-like implants for the face. Some fillers are gradually absorbed by the body over time. Healthcare providers administer these fillers through injections to enhance the appearance of specific skin areas. The influence of social media has contributed to the growing popularity of dermal fillers among both the youth and adult population, as they seek to enhance their attractiveness.

The increasing geriatric population and growing awareness about dermal fillers across Europe contribute to the growth of the European dermal fillers market. As the population ages, visible skin changes become more prevalent. The human face consists of various layers, including skin, subcutaneous fat, muscles, deep fat compartments and bones. Aging can lead to volume loss and damage in these layers, necessitating the use of dermal fillers to restore the face's natural appearance. Dermal fillers effectively address issues such as fine lines, skin sagging, and loss of facial volume.

The growing development of advanced dermal fillers propels the European market growth. Researchers are focused on extending the duration of fillers beyond 12 months to meet the rising demand. Additionally, they are working on developing dermal fillers for various body parts to enhance their appearance. Factors such as increasing investment in research and development, support from public and private organizations, favorable reimbursement policies, and the presence of key players promote the growth of the European dermal fillers market.

Factors such as the high cost of fillers, the lack of skilled professionals, and the awareness and availability of filler products hamper the growth of the dermal fillers market in Europe. Side effects such as redness, allergies, swelling, pain, bruising, itching, and rashes are associated with dermal fillers. The use of non-approved injectable dermal fillers presents further challenges to market growth

This research report on the North America dermal fillers market has been segmented & sub-segmented into the following categories:

By Product: 

• Absorbable or Biodegradable
• Non-Absorbable or Non-Biodegradable

By Therapeutic Area: 

• Wrinkles
• Deep Facial Lines
• Sagging Skin
• Scars

By Country: 

• The United States
• Canada
• Rest of North America

North America held the largest share of the global market in 2022 and the domination of the North American region is expected to continue throughout the forecast period due to advancements in facial surgeries, availability of advanced infrastructure facilities, mergers and acquisitions and rising healthcare expenditure. The U.S. is expected to hold the major share of the North American market during the forecast period owing to the support from the U.S. government for dermal filler approvals by the FDA. The efforts from the key market participants in creating awareness through social media and advertisements boost the U.S. market growth. Canada is predicted to account for a substantial share of the North American market in the coming years due to the growing number of beauty clinics, skin specialists, and the adoption of minimal invasion surgeries, supported by pharmaceutical companies and manufacturing facilities.

KEY MARKET PLAYERS:

A few of the noteworthy companies operating in the North American Dermal Fillers Market profiled in this report are Allergan Inc., AQTIS Medical, Bio ha Laboratories, Suneva Medical, Galderma, Merz Aesthetics, Cynosure, Syneron, Cytophil Inc.